Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments

• Published in: Brain, behavior, & immunity. Health behavior, & immunity. Health, 2022-12, Vol.26, p.100554-100554, Article 100554
• Main Authors: Richardson, Brandon, MacPherson, Andrew, Bambico, Francis
• Format: Article
• Language: English
• Subjects: Cytokine; Depression; Inflammation; Major depressive disorder (MDD); Neuroplasticity; Neuroprogression; Review; Serotonin; Treatment
• ISSN: 2666-3546; 2666-3546
• DOI: 10.1016/j.bbih.2022.100554

Given that available antidepressant pharmacotherapies are not optimally effective, there is a need for alternative treatment options that are rooted in a comprehensive understanding of the illness's pathophysiology. Major depressive disorder (MDD) has been historically attributed to monoamine, i.e., serotonin (5-hydroxytryptamine, 5-HT) imbalance and some brain morphological pathologies that have directed treatment towards particular medications that are only minimally effective. MDD pathophysiologies have now been regarded as linked to chronic inflammation and MDD can be treated with compounds that have anti-inflammatory properties. Individuals vulnerable to MDD have increased baseline neuroinflammatory response that is exacerbated by psychogenic stress. When pro-inflammatory mechanisms are chronically hyperactive, dysfunction of brain-related processes occur. We propose that inflammation is one of the primary mechanisms that trigger biological changes leading to MDD. Inflammatory resolution occurs when homeostasis is achieved after an inflammatory response. However, cascading biological events are likely to prevent resolution from occurring and worsen both inflammation and MDD. Novel and alternative pharmacotherapies—e.g., ketamine, cannabinoids, and psychedelics—provide a richer mechanistic perspective on the role of neuroinflammation and neuroprogression by means of rapid, short-term, and long-term symptom relief potentially based on their anti-inflammatory properties. These drugs ultimately decrease proinflammatory cytokine levels that correspond with improved symptoms. However, it is unclear what differentiates these compounds from others in their mechanistic efficacy. Thus, a closer investigation into their anti-inflammatory effects is imperative in order to better elucidate the link between MDD and inflammation, as well as uncover the mechanisms involved in long-term symptom reduction of MDD. •Chronic and hyperactive inflammation is heavily implicated in the development of depression.•Dysfunction of inflammatory mechanisms induces perpetual inflammation linked to the onset and duration of depression.•Treatment of inflammation also treats some depression (e.g., SSRI's).•Effective long-term treatment of depression is likely rooted in inflammatory resolve.•Propose alternative treatments for depression provide novel insights into the role of inflammation in depression.